Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day
11/07/2022 - 08:00 AM
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day, to be held in-person in New York, NY from November 14-15, 2022.
Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day Click Here
To schedule a meeting with the Company, please contact your Guggenheim representative.
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com .
About Selecta Biosciences, Inc. www.selectabio.com .
For Investors: bmackle@lifesciadvisors.com
For Media: bleigh@lifescicomms.com
SELB Rankings
#3456 Ranked by Stock Gains
SELB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Watertown
About SELB
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
